$709 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 106 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 81.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TARS | Buy | TARSUS PHARMACEUTICALS INC | $38,038,213 | +18.3% | 2,140,586 | +20.3% | 5.37% | +13.4% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $33,130,522 | +38.8% | 3,440,345 | +29.8% | 4.68% | +33.1% |
| IMGN | Buy | IMMUNOGEN INC | $23,805,000 | -3.0% | 1,500,000 | +15.4% | 3.36% | -7.0% |
| New | EQRX INC | $22,391,164 | – | 10,086,110 | +100.0% | 3.16% | – | |
| NTLA | New | INTELLIA THERAPEUTICS INC | $12,572,112 | – | 397,600 | +100.0% | 1.77% | – |
| AVIR | Buy | ATEA PHARMACEUTICALS INC | $10,800,000 | -4.6% | 3,600,000 | +19.0% | 1.52% | -8.5% |
| AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $10,300,000 | – | 1,000,000 | +100.0% | 1.45% | – |
| BIO | Buy | BIO RAD LABS INCcl a | $8,602,800 | +41.8% | 24,000 | +50.0% | 1.21% | +35.9% |
| New | DIANTHUS THERAPEUTICS INC | $8,087,664 | – | 591,636 | +100.0% | 1.14% | – | |
| NVCR | Buy | NOVOCURE LTD | $7,947,415 | +91.5% | 492,100 | +392.1% | 1.12% | +83.5% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $7,840,800 | +171.3% | 180,000 | +125.0% | 1.11% | +159.6% |
| BCAB | Buy | BIOATLA INC | $6,423,268 | -41.7% | 3,778,393 | +2.8% | 0.91% | -44.2% |
| QURE | New | UNIQURE NV | $6,279,218 | – | 935,800 | +100.0% | 0.89% | – |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $5,827,500 | +301.3% | 750,000 | +400.0% | 0.82% | +284.1% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $5,621,299 | +16.1% | 621,138 | +38.0% | 0.79% | +11.2% |
| EQC | Buy | EQUITY COMWLTH | $5,511,000 | +172.0% | 300,000 | +200.0% | 0.78% | +161.1% |
| AVRO | Buy | AVROBIO INC | $5,409,536 | +110.5% | 3,512,686 | +29.9% | 0.76% | +101.9% |
| ADMA | Buy | ADMA BIOLOGICS INC | $4,868,800 | +4.7% | 1,360,000 | +7.9% | 0.69% | +0.4% |
| ADAP | Buy | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $4,030,224 | -10.8% | 5,166,954 | +5.7% | 0.57% | -14.6% |
| BOLT | Buy | BOLT BIOTHERAPEUTICS INC | $3,699,322 | -13.3% | 3,557,040 | +6.7% | 0.52% | -16.9% |
| Buy | ASLAN PHARMACEUTICALS LTDspon ads new | $3,574,918 | -13.2% | 1,901,552 | +68.6% | 0.50% | -16.8% | |
| DSGN | New | DESIGN THERAPEUTICS INC | $3,186,000 | – | 1,350,000 | +100.0% | 0.45% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $3,073,500 | – | 150,000 | +100.0% | 0.43% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $2,982,000 | – | 200,000 | +100.0% | 0.42% | – |
| Buy | LIANBIOsponsored ads | $2,682,000 | +22.3% | 1,800,000 | +87.1% | 0.38% | +17.0% | |
| NKTR | Buy | NEKTAR THERAPEUTICS | $2,346,426 | +2822.1% | 3,939,600 | +2722.1% | 0.33% | +2658.3% |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $2,084,000 | – | 100,000 | +100.0% | 0.29% | – |
| PDSB | Buy | PDS BIOTECHNOLOGY CORP | $2,020,000 | +301.6% | 400,000 | +300.0% | 0.28% | +285.1% |
| New | BIONOMICS LIMITEDads | $1,890,000 | – | 700,000 | +100.0% | 0.27% | – | |
| KRTX | New | KARUNA THERAPEUTICS INC | $1,690,900 | – | 10,000 | +100.0% | 0.24% | – |
| New | JOURNEY MED CORP | $1,578,514 | – | 576,100 | +100.0% | 0.22% | – | |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $1,148,000 | – | 400,000 | +100.0% | 0.16% | – |
| TGTX | New | TG THERAPEUTICS INC | $836,000 | – | 100,000 | +100.0% | 0.12% | – |
| LIFE | Buy | ATYR PHARMA INC | $744,392 | +129.8% | 471,134 | +214.1% | 0.10% | +118.8% |
| GOSS | New | GOSSAMER BIO INC | $698,386 | – | 838,600 | +100.0% | 0.10% | – |
| GRCL | New | GRACELL BIOTECHNOLOGIES INCsponsored ads | $458,171 | – | 159,087 | +100.0% | 0.06% | – |
| MOLN | Buy | MOLECULAR PARTNERS AGads | $414,000 | +67.4% | 100,000 | +151.6% | 0.06% | +61.1% |
| New | XERIS BIOPHARMA HOLDINGS INC | $279,000 | – | 150,000 | +100.0% | 0.04% | – | |
| PASG | Buy | PASSAGE BIO INC | $263,200 | -6.8% | 400,000 | +33.3% | 0.04% | -11.9% |
| New | TRANSCODE THERAPEUTICS INC | $42,232 | – | 84,010 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.